May 23 |
Esperion's (ESPR) Drugs Get EU Nod for Lowering Heart Risk
|
May 23 |
Esperion to Participate in Upcoming June Investor Conferences
|
May 22 |
First-In-Class Cholesterol-Lowering Treatment NILEMDO® (NEXLETOL® in the U.S.) and Its Combination with Ezetimibe, NUSTENDI® (NEXLIZET® in the U.S.), Approved In Europe To Treat Hypercholesterolemia and Significantly Reduce Cardiovascular Risk
|
May 20 |
Esperion's late stage trial of high cholesterol treatment met main goal
|
May 20 |
Bempedoic Acid Met Primary Endpoint of Phase 3 Trial in Japan for the Treatment for Hypercholesterolemia
|
May 20 |
Buy Esperion Therapeutics Despite An Abiding Skepticism Weighing On The Stock
|
May 14 |
Esperion Receives Five Year Patent Extension for Bempedoic Acid, Contained in NEXLETOL® and NEXLIZET®
|
May 10 |
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
|
May 8 |
Esperion (ESPR) Q1 Earnings Beat, Stock Up on Strong Revenues
|
May 8 |
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q1 2024 Earnings Call Transcript
|